We congratulate Lartigau and colleagues [
[1]
] on their assessment of “Multi institutional phase II study of concomitant stereotactic
reirradiation and cetuximab for recurrent head and neck cancer.” However, we would
like to raise several points regarding this issue.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Radiotherapy and OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.Radiother Oncol. 2013; 109: 281-285
- Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients.Int J Radiat Oncol Biol Phys. 2005; 61: 851-855
- Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.Radiother Oncol. 2011; 100: 70-75
- Quality of life research in head and neck cancer: a review of the current state of the science.Crit Rev Oncol Hematol. 2007; 62: 251-267
Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol 2013;49:443–8.
- Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.Lancet Oncol. 2009; 10: 865-871
Reirradiation and Erbitux in the HNSCC (accessed 2013, at Clinicaltrials.gov/ct2/show/NCT01237483).
- Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.Int J Radiat Oncol Biol Phys. 2012; 84: 203-209
Article info
Publication history
Published online: March 17, 2014
Accepted:
January 21,
2014
Received:
January 17,
2014
Identification
Copyright
© 2014 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
